Receptor tyrosine kinases and anticancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Protein tyrosine kinases (PTKs) are crucial enzymes regulating cellular signaling pathways.
• Dysregulation of PTKs is implicated in various cancers, driving tumor and tumor vessel growth.
• Targeting PTKs has emerged as a significant strategy in cancer therapy.

Purpose of the Study:

• To review novel drugs targeting protein tyrosine kinases for cancer treatment.
• To highlight the role of specific tyrosine kinase inhibitors and antibodies in oncology.
• To discuss the clinical investigation and approval status of various PTK-targeting agents.

Main Methods:

• Literature review of preclinical and clinical studies on tyrosine kinase inhibitors.
• Analysis of drug development targeting specific kinases like BCR-Abl, c-kit, EGFR, and HER2/neu.
• Examination of agents targeting tumor angiogenesis via VEGF and multi-target inhibitors.

Main Results:

• Several tyrosine kinase inhibitors and antibodies are approved or in clinical trials for cancer treatment.
• The efficacy of these drugs is linked to the specific tyrosine kinase targeted and its expression level in tumors.
• Targeted therapies demonstrate a new modality for treating various cancer types.

Conclusions:

• Targeting protein tyrosine kinases represents a promising approach in modern cancer therapy.
• The development of specific and multi-target tyrosine kinase inhibitors continues to advance cancer treatment options.
• Expression profiling of kinases in tumors is essential for guiding therapeutic indications.